Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alterity Therapeutics ADR ATHE

Healthcare Biotechnology
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the... see more

Recent & Breaking News (NDAQ:ATHE)

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

GlobeNewswire October 2, 2024

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

GlobeNewswire September 30, 2024

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

GlobeNewswire September 23, 2024

Appendix 4C - Q4 FY24 Quarterly Cash Flow Report

GlobeNewswire July 31, 2024

Alterity Therapeutics to Present at MST Financial Webinar

GlobeNewswire July 24, 2024

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

GlobeNewswire July 17, 2024

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

GlobeNewswire July 17, 2024

Alterity Therapeutics to Present at the MST Access 'Hidden Gems in Life Sciences' Webinar

GlobeNewswire June 12, 2024

Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

GlobeNewswire May 29, 2024

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

GlobeNewswire May 8, 2024

Appendix 4C - Q3 FY24 Quarterly Cash Flow Report

GlobeNewswire April 30, 2024

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's Ataxia

GlobeNewswire April 29, 2024

Alterity Therapeutics Parkinson's Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

GlobeNewswire April 17, 2024

Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024

GlobeNewswire April 10, 2024

Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund

GlobeNewswire March 26, 2024

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting

GlobeNewswire February 20, 2024

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

GlobeNewswire February 6, 2024

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

GlobeNewswire January 29, 2024

Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones

GlobeNewswire January 22, 2024

Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer

GlobeNewswire December 21, 2023